Director Leon Recanati Buys $292K of Evogene Shares Amid Activist Fight
EVGN sits 76% above its 52-week low of $0.37 on light trading volume (0.3× avg).
Summary
Director Leon Recanati bought $292,100 of Evogene stock, increasing his stake to 8.6% amid an activist board challenge.
Key Events · Ownership and Investor Activity · EVGN
-
Director Buys $292K in Open Market
Leon Recanati purchased 460,000 shares at $0.635 per share on August 11, 2026, for $292,100.
-
Stake Rises to 8.6%
Recanati now beneficially owns 1,354,836 shares, including 10,950 options, representing 8.6% of outstanding shares.
-
Purchase Amid Activist Proxy Fight
The buy comes as an activist group seeks to replace the board, and follows the company's ATM offering and recent losses.
-
Insider Accumulation Signal
This is the only open-market insider purchase in the last 90 days, totaling $292,100, indicating director-level conviction.
Analysis · EVGN · Industrial Applications And Services
Director Leon Recanati purchased 460,000 shares at $0.635 on August 11, 2026, raising his stake to 8.6%. This $292,100 open-market buy comes during an activist proxy battle and after the company's ATM offering, signaling insider confidence at a depressed price.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVGN was trading at $0.65 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $9.7M. The 52-week trading range was $0.37 to $1.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.